Named people, with numbers attached
The homepage names a head of pharmacy with a doctorate and a state licence number, and a board-certified physician with a national provider identifier. Both numbers are printed, which turns a claim about credentials into something a reader can check against a public register.
That is rare here. The usual formulation is a reference to licensed providers, which names nobody and can be verified by nobody.
A state list, not a state claim
Its FAQ answers the coverage question with thirty-five states set out by name, and says plainly that it is adding more. Fifteen states are therefore not served, and the page does not hide that.
A published list is worth more than a fifty-state banner, because it can be wrong in a way a reader can detect.
Brand-name pens, and a cycle that is not a month
There is no compounded lane here at all. Three brand-name weekly pens are sold for cash, each with a first-cycle figure, an ongoing figure and a checkout code.
Every tile ends with the same sentence: billed and shipped approximately every four weeks. That is thirteen charges in a calendar year, not twelve, and it is the seller who says so rather than a reviewer who worked it out.
We store all three as non-monthly rates for that reason. Anyone annualising the headline by twelve will understate the year by about a thirteenth, and the correction is printed on the page they read it from.
What is unresolved
Two corporate names attach to this brand. The footer copyright uses one and the FDA's warning letter uses another, differing by a word. We record both rather than deciding which is current.
No dispensing pharmacy is named as a business, and no membership position is stated anywhere — the tiles say only that a subscription can be cancelled at any time, which answers a different question.
Every advertised figure is discounted from the standing one, so the number a reader sees first is a promotion. To its credit, the standing figure is printed beside it rather than in a footnote.
It carries an FDA warning letter issued in February 2026 over false and misleading claims and misbranding. That is a disclosure and it does not move this seller's position here.
Levity's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (brand) | $1,299the ongoing rate, and the seller states the cycle itself — "$1,299/mo thereafter. Billed & shipped approx. every 4 weeks." Thirteen four-week cycles fall in a calendar year, not twelve, so this is not a monthly figure. The first cycle is listed at $1,249 against a $1,299 list price, with a checkout code | September 2026source |
| Semaglutide (brand) | $1,599the ongoing rate — "$1,599/mo thereafter. Billed & shipped approx. every 4 weeks", so the same thirteen-cycle arithmetic applies. The first cycle is listed at $1,549 against a $1,599 list price, with a checkout code | September 2026source |
| Semaglutide (brand) | $1,199the ongoing rate — "$1,199/mo thereafter. Billed & shipped approx. every 4 weeks"; the tile describes it as the "Same ingredient as Wegovy but with a lower max dose". The first cycle is listed at $1,149 against a $1,199 list price, with a checkout code | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 264 providers reviewed here are paid partners today; the other 260 are not. See how this works.
See Levity's current price →Good fit if
- Cash buyers who want a brand-name pen rather than a compounded preparation.
- Readers who want to look up the prescriber and the pharmacist before they buy.
- People who want their state confirmed on a published list, not by starting an intake.
- Anyone who wants the billing cycle stated rather than implied.
Look elsewhere if
- Buyers looking for a low monthly figure — everything here is priced at brand-name cash rates.
- Readers in the fifteen states the list does not name.
- Anyone who needs a compounded option as a fallback.
- Buyers who want the dispensing pharmacy named as a business.
How this review was verified
- Read the homepage on 7 September 2026, comparing requested to effective URLs, with a nonsense path on the same host in the same run, which returned a 404.
- Confirmed that the two product paths an earlier research file named both return 404, so every figure here was taken from the homepage tile that carries it, with the tile's own billing sentence.
- Copied the state list from the FAQ answer in full and counted it rather than trusting a summary, then recorded the fifteen absent states as a gap.
- Recorded both the first-cycle and the ongoing figure for each product, and stored the ongoing one as the price.
- Screened the live FDA warning-letter datatable by entity name with a positive control returning exactly one row and a nonsense control returning none, then fetched the letter and confirmed its body names this seller's domain.